These medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and are not recommended during pregnancy
In terms of dosage form design, relying on the stable properties of this powder, mainstream products now achieve a once-weekly injection dosing regimen, significantly reducing the medication burden on patients compared to the previous daily injection schedule
Retatrutide (12mg): Up to 28.7% body weight reduction over 68 weeks in TRIUMPH-4
Because Tesamorelin is a GHRH analog, the research/clinical framing tracks IGF-1 (to avoid excessive elevation) and blood glucose (GH is counter-regulatory to insulin)
NOVO NORDISK A/S, NOVO NORDISK INC
In the SURMOUNT-1 trial, tirzepatide demonstrated even more substantial results, with some participants losing over 20% of their starting weight